Diagnostic Services

Your metabolizer profile, read with the rest.

Pharmacogenetic testing at The Stepwell Center is a DNA-based test that identifies how your body metabolizes psychiatric medications. The report is one of four diagnostic inputs in our 2 to 3 day comprehensive assessment in Lakeway, Texas. Same-day or next-day admission to the assessment.

Schedule an assessment 512.743.9285

What the test actually is

Pharmacogenetic testing, in plain language.

Pharmacogenetic testing reads the DNA you already carry and translates it into a map of how your body processes psychiatric medications. The report is read alongside the rest of your assessment, never as a standalone prescription.

Pharmacogenetic testing is a DNA-based laboratory test that identifies how your body metabolizes specific psychiatric medications. The result is a metabolizer profile, drawn from variants in the cytochrome P450 enzyme genes (CYP2D6, CYP2C19, CYP2B6) and a small set of related markers, that maps onto how quickly your body breaks down or activates each medication class. The FDA Table of Pharmacogenomic Biomarkers in Drug Labeling lists more than thirty psychiatric medications where this information already appears on the official prescribing label.

At Stepwell, pharmacogenetic testing is one of the four diagnostic inputs in the comprehensive assessment program, alongside qEEG brain mapping, a neurofeedback baseline, and standardized psychological testing. The profile narrows the first-trial selection of medication where prior trials have not delivered relief, and it informs dosing conversations. The 2023 CPIC guideline for serotonin reuptake inhibitor antidepressants is the canonical reference clinicians use to translate metabolizer status into prescribing recommendations.

The clinical case for pharmacogenetic-guided prescribing in major depressive disorder has matured. A 2023 NIH meta-analysis of eleven randomized controlled trials covering 5,347 patients reported higher response and remission rates with pharmacogenetic-guided antidepressant prescribing compared to usual care. At Stepwell, the profile is one input, not the verdict. It is read with the rest of our diagnostic services at our Lakeway, Texas facility before any medication recommendation is made.

A Hispanic-Latino man in his early 40s with a clean-shaven shaved head, sage linen overshirt over a fitted cream tee and dark olive linen trousers, seated three-quarter profile on the weathered cedar plank top step of a covered Hill Country back porch, both hands resting on his knees, calm grounded gaze on the soft Hill Country horizon, terracotta-potted lavender and young agave flanking the step, native silver salvia in low beds, a single live-oak branch framing the upper right, warm golden afternoon Hill Country light.

Inside the test

What the cheek swab actually does.

You arrive for the pharmacogenetic sample on the first or second day of the comprehensive assessment in Lakeway. A clinician collects a brief cheek swab using a sterile collection kit. The sample is then sent to an accredited clinical laboratory. The collection itself takes only a few minutes and is not painful.

Lab results typically return within five to ten business days. The report identifies your metabolizer status across the cytochrome P450 enzymes that process most psychiatric medications, showing which classes may be processed normally, which may be processed too quickly to reach therapeutic levels, and which may accumulate. The report covers SSRIs, SNRIs, tricyclic antidepressants, and several adjacent classes.

Your prescriber reads the metabolizer profile alongside your qEEG, neurofeedback baseline, psychological testing, and clinical interview before any medication recommendation is made. The report is one of four diagnostic inputs in your assessment, read together rather than in isolation, and the integrated read is what shapes your prescribed level of care.

Schedule an assessment

How the result gets used

Three things the result does.

  1. Narrows medication choices

    Your metabolizer profile guides first-trial selection across SSRIs, SNRIs, tricyclic antidepressants, and related psychiatric medication classes, so your prescriber starts from informed ground rather than trial and error.

  2. Informs dosing conversations

    Variants in CYP2D6 and CYP2C19 may prompt your prescriber to adjust a starting dose, drawing on CPIC guidance. The profile is read alongside your symptoms, history, and the rest of your assessment, never as the dose by itself.

  3. Reads with the rest of your plan

    The pharmacogenetic profile is one of four diagnostic inputs in the comprehensive assessment, integrated with qEEG, psychological testing, and your clinical interview before the prescribed treatment plan is written.

Common Questions

Questions families send us most.

Pulled from the questions families and prospective patients ask most often when considering pharmacogenetic testing at Stepwell.